(Q50627434)

16 March 2018

title

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. (English)

1 reference

16 March 2018

postmenopausal osteoporosis

main subject

osteoporosis

0 references

1 reference

Miller PD

1

1 reference

16 March 2018

Watts NB

2

1 reference

16 March 2018

Licata AA

3

1 reference

16 March 2018

Harris ST

4

1 reference

16 March 2018

Genant HK

5

1 reference

16 March 2018

Wasnich RD

6

1 reference

16 March 2018

Ross PD

7

1 reference

16 March 2018

Jackson RD

8

1 reference

16 March 2018

Hoseyni MS

9

1 reference

16 March 2018

Schoenfeld SL

10

1 reference

16 March 2018

Valent DJ

11

1 reference

16 March 2018

Chesnut CH 3rd

12

1 reference

16 March 2018

language of work or name

English

0 references

publication date

1 December 1997

1 reference

16 March 2018

American Journal of Medicine

published in

1 reference

16 March 2018

volume

103

1 reference

16 March 2018

issue

6

1 reference

16 March 2018

page(s)

468-476

1 reference

16 March 2018

Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Prevention of glucocorticoid-induced osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Vertebral fracture assessment using a semiquantitative technique.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Bisphosphonates act on rat bone resorption through the mediation of osteoblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Structural requirements for bisphosphonate actions in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Use of nasally administered salmon calcitonin in preventing bone loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Etidronate disodium in postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Etidronate disodium in the treatment of Paget's disease of bone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Pamidronate: an unrecognized problem in gastrointestinal tolerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

Esophagitis associated with the use of alendronate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900278-7

10.1016/S0002-9343(97)00278-7

7 January 2021

Identifiers

DOI

1 reference

16 March 2018

1 reference

16 March 2018